Floatz logo

Dexrazoxane

Angioimmunoblastic T-cell Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

55 Active assets in the Angioimmunoblastic T-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
Shandong Provincial Hospital
Phase 4BBB
DEXAMETHASONE
Ou Bai, MD/PHD
Phase 2BB
ETOPOSIDE
Eric Jacobsen, MD
Phase 4BB
Romidepsin
The Lymphoma Academic Research Organisation
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Dexrazoxane is also rated in:

diffuse large B-cell lymphomaDormant
B
Indicative ·
60 / 100
View asset →
childhood acute lymphoblastic leukemiaDormant
B
Indicative ·
59 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →